Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of elotuzumab in clinical practice in Japan.
Epistemonikos ID: 5e1aeddf1fec54dab0eaf872f6e90563741b8277
First added on: May 20, 2024